During this webinar, the speaker will share ideas and practical examples on innovative approaches to antibacterial discovery to meet the augmented needs of the market and to tackle antibacterial resistance issues. The presentation will also highlight the importance of a tailored redesign of in vitro and in vivo tools to accelerate the antibacterial discovery effort.
RAND Europe’s study has in fact demonstrated that delaying the development of widespread resistance by just 10 years could save 65 trillion USD of the world’s output between now and 2050, and the projected 10M deaths attributable to antimicrobial resistance every year until 2050.
Antonio Felici, PhD, Senior Manager, Head of Microbiology, Aptuit Center for Drug Discovery & Development – Verona, Italy
Antonio Felici holds a PhD in Enzymology and Applied Biochemistry from the Centre of Protein Engineering (University of Liege, Belgium) where he started his scientific journey on elucidating the mechanism of inactivation of ß-lactam antibiotics by ß-lactamases. After his PhD he joined the Microbiology Department at the GlaxoWellcome Discovery Centre based in Verona, Italy, with the responsibility for teams involved in the characterization of new antibiotics. Later on he led the Microbial Biochemistry laboratory at the Centre of Excellence for Drug Discovery in the newly formed GSK organization, focussing on the elucidation of the intimate mechanism of actions of new antibacterial compounds. During this period he was involved in the study of regulation of bacterial virulence, quorum sensing, biofilm formation, identification of new bacterial targets as well as in the management of specific strategic partnerships with other Companies. He joined the Drug Design and Discovery Unit of the newly established Aptuit Center for Drug Discovery & Development where he is responsible of the Microbiology Department.
Antonio is a member of the American Society for Microbiology (ASM) and Project Management Institute (PMI).
Who Should Attend?
- Microbiology / Drug Discovery Heads/Managers
- Project / Program Leaders
- Lead Analysts
- Clinical Practitioners
- Regulatory Managers and Specialists
Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the Pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, and Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery and development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains resources around the world, with facilities in the US, UK and Italy. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.
For more information about Aptuit, visit www.aptuit.com.